The membership of the ACS may elect additional Council members to advise the executive council and provide adequate representation of the membership, for example in terms of cytometry field (research, clinical, industrial) or geographical area (Australia, New Zealand). Additional Council members shall serve until the next Annual General Meeting.
Current Advisory Council:
Rob Salomon is an experienced cytometerist and technical scientist that is motivated to drive the advancement of science through the appropriate use of technology. This involves both the effective utilization of current technology as well as the development and/or application of novel technologies. Rob is a scientifically trained technologist that has driven large projects and built effective teams to leverage cutting-edge technologies for the advancement of science. He is inspired to:
- Advance Science
- Progress the understanding of disease and biological processes
- Help researchers achieve their goals
- Work within as well as lead cohesive teams where highly skilled specialists can work in a collaborative manner to achieve outcomes that would not be possible individually
- Leverage technological solutions to help answer big questions
- Identify synergies between previously disparate technologies to provide seamless solutions to simplify complex processes
Since 2015, Rob has been working to advance the field of Genomic Cytometry. This is evidenced by his driving role in the design, planning and implementation of the Garvan-Weizmann Centre for Cellular Genomics. Rob, along with the team he built and with support from the Garvan Institute, successfully conceived, funded and built the centre. The centre is the only one of its kind in Australia and is unique in the world in that it brings the previous disparate modalities of cytometry, microfluidics, genomics and bioinformatics under the one roof. Most recently, Rob has been Working at the University of Technology Sydney with the Institute of Biomedical Materials and Devices (IBMD) and the Children’s Cancer Institute of Australia (CCIA) where he lead the technology design for the recently announced ACRF Child Canner Liquid Biopsy Program.
Rob has been involved with the ACS since beginning in cytometry in 2004. He has filled a number of positions with the ACS including, Website committee member, Treasurer and is currently the ACS Industry and Innovation liaison member. In his role with ACS he is passionate about bringing new technologies and approaches to the field of Cytometry and is looking to provide support for innovation and to improve connections between industry and academia.
Dr Henry Hui
Dr Henry Hui is an early career research associate at the Translational Cancer Pathology Laboratory (University of Western Australia) and a Marylou Ingram Scholar (International Society for the Advancement of Cytometry). His internationally recognised research charters the intersection of cytometry technology and cutting-edge methodologies (protocol development) to leverage new frontiers in biological discovery and clinical application.
Since 2013, Henry has driven the expansion of an award-winning, multidisciplinary research team that leads the world in imaging flow cytometry powered diagnostic developments for haematological malignancies and constitutional disorders in adults, children, and neonates. He is the co-inventor of the world-first “Immuno-flowFISH” method, a game-changing diagnostic test leveraging the capabilities of imaging flow cytometry. This invention enables precision assessment of blood cancers that vastly exceeds current research and clinical testing modalities. In 2018, he was awarded the highly prestigious ANSTO 2018 Eureka Prize for Innovative Use of Technology by the Australian Museum. Henry’s innovations have been patented in many countries and his cytometry expertise has drawn funding equivalent to $2.9M in value from industry partnerships, government grants and health-care organisations.
Henry has established global multidisciplinary collaborative networks that intersect research, academia, clinical and industry commercialisation pipelines. He currently collaborates with local tertiary hospitals, health care providers, large medical technology corporations (Luminex Corporation, USA and Sysmex Corporation, Japan) and world class diagnostic cancer centres (MD Anderson Cancer Centre, Texas USA and University of Cambridge, UK) for the global adoption of cytometry powered “bench to bedside” innovations. His long-term goal as a scientist is to lead the innovation, application, influence, education, engagement, and outreach of cytometry in both scientific and clinical domains, to advance knowledge and health globally.
Dr David Sester
Dave oversees operation of the TRI flow cytometry suite (TRI.fcs) at the Translational Research institute, based at the Princess Alexandra Hospital precinct in Woolloongabba, Brisbane. The TRI.fcs services users from its shareholders including the University of Queensland, Mater Research Institute and Queensland University of Technology in addition to external clients from the South-East Queensland area.
In a former life he was a research scientist, who’s exposure to flow cytometry commenced in 1995 on a BD FACSCalibur. With 40+ publications (h index 30), he continues to be involved with research projects, assisting researchers with their flow cytometry needs particularly in relation to high-dimensional panel design, cell sorting strategies and imaging cytometry applications. Since switching to the core facility world, Dave has continued his passion of educating and helping researchers as to become better cytometrists.
Teresa Marzulli is a Senior Hospital Scientist at the Children’s Hospital at Westmead, Sydney, NSW, Australia , where she manages both the Haematology laboratory as well as its Flow Cytometry service. The latter laboratory mainly focuses on Haematological malignancies as well as Measurable Residual Disease in Paediatric patients. She has been instrumental in the development of Flow Cytometry services in both private and public sectors and she is quite passionate about standardisation, ongoing competency, continuing education, as well as process, analytical and clinical improvement in Flow Cytometry. Her flow cytometry experience spans over 10 years and her passion is predominately in childhood leukaemia for which she has presented at numerous conferences and workshops. She has recently joined the ACS committee and is looking forward to contributing to promoting the advancement of clinical flow cytometry.